Robert Coleman – författare

Gynecologic oncology takes a fresh look at a critical aspect of cancer treatment planning. An international team of authors reviews the traditional prognostic and predictive factors such as tumor grade, histologic subtype, and grade and then goes a step further to review the growing number of molecular discoveries that have increasing clinical significance. The book is organized into comprehensive sections on ovarian, endometrial and cervical cancer and includes up to date reviews, newly discovered molecular pathways, genetic markers, molecular imaging techniques, and their relevance to clinical medicine.

Prognostic and Predictive Factors in Gynecologic Oncology is illustrated with over 100 figures and is essential reading for oncologists, translational and basic scientists, as well as fellows, residents and students with a special interest in gynecologic oncology.

Gynecologic oncology takes a fresh look at a critical aspect of cancer treatment planning. An international team of authors reviews the traditional prognostic and predictive factors such as tumor grade, histologic subtype, and grade and then goes a step further to review the growing number of molecular discoveries that have increasing clinical significance. The book is organized into comprehensive sections on ovarian, endometrial and cervical cancer and includes up to date reviews, newly discovered molecular pathways, genetic markers, molecular imaging techniques, and their relevance to clinical medicine.

Prognostic and Predictive Factors in Gynecologic Oncology is illustrated with over 100 figures and is essential reading for oncologists, translational and basic scientists, as well as fellows, residents and students with a special interest in gynecologic oncology.

This book provides a history and discussion of the use of human tissues as an alternative to animal-based testing for assessing the efficacy and safety of new medicines. Beginning by providing a historical background to animal-based testing, this text then describes in detail the issues relating to access to human cells and tissue and the rules and regulations governing their use. The book illustrates what is currently possible in humanising medicines research and development, and suggests more rational and reliable means of developing safe and effective drugs for the future than those on which we currently rely. Early chapters establish the need to generate more data in human-derived test systems, and the need for resources such as tissue banks and standardised processes whilst highlighting the barriers that have prevented such developments so far. Subsequent chapters explore the alternatives to current animal toxicology studies, including stem cells and computational models, with balanced views of the technical challenges and opportunities these offer. In addition, useful information on computational methods and pharmacokinetics are included. This book is an essential read for anyone engaged in translational drug discovery who wishes to consolidate their understanding and broaden their awareness of the key issues involved in accessing primary human tissue and the advantages of doing so.